提醒：公司访问-劳森的催化剂与关键辩论电话会议；施罗德公司美国东部时间明天上午11:00

Updated Lineup – Additional Calls to Be Added as Confirmed•Wednesday 05/28 at 11:00am ET:•°Schrodinger Inc (SDGR) - Ramy Farid (CEO), Karen Akinsanya (President of R&D)°°1X1s available:11:30 AM ET,°•Thursday 06/05 at 11:30am ET:•°Day One Biopharma (DAWN) - Jeremy Bender (CEO), Charles York (COO/CFO)°•Thursday, 06/12 at 10:00am ET:•°Olema Pharmaceuticals Inc (OLMA) - Sean Bohen (CEO), Shane Kovacs (COO/CFO)°°1X1s available:10:30 AM ET, 11:00AM ET, 11:30 AM ET°•Monday, 06/16 at 11:00am ET:•°Recursion Pharma Inc (RXRX) - Najat Khan (Chief R&DOfficerandCCO), Ben°Taylor (CFO)•Wednesday, 06/18 at 1:30pm ET:•°Incyte Corp (INCY) - Christiana Stamoulis (CFO), Pablo Cagoni (Head of R&D)°°1X1s available:2:00 PM ET, 2:30 PM ET, 3:00 PM ET, 3:30 PM ET°Past calls•05/05•°Immunome (IMNM) - Clay Siegall (CEO)°•05/08•°Ideaya (IDYA) - Darrin Beaupre (CMO) and Mike White (CSO)°•05/15•°Bicara Therapeutics (BCAX) - Claire Mazumdar (CEO), Ryan Cohlhepp (President/°COO), Ivan Hyep (CFO)•05/19•°Tango (TNGX) - Barbara Weber (CEO), Daniella Beckman (CFO)°•05/20•°Nurix (NRIX) - Arthur Sands (CEO), Hans van Houte (CFO), Jason Kantor (CBO)° Peter Lawson, DPhil(Oxon)+1 212 526 9445BCI, USMeet the AnalystU.S. Small & Mid Cap BiotechnologyThis event is intended for Barclays institutional investor clients only. This event is strictly and solelyfor the benefit of the intended recipients. Please do not forward this invitation to any other partywithout written consent from Barclays Research. Barclays' Investment Bankers are prohibited fromattending this event. Participant comments are not for attribution.If your firm is in-scope for research unbundling under MiFID II and you require further informationregarding pricing to participate in this Barclays Research content event, please contact your salesrepresentative.Barclays Events Terms of Service | Barclays Events Privacy NoticeDisclaimer:BARCLAYSThis communication has been prepared by Barclays.“Barclays” means any entity within the Barclays Group of companies, where “Barclays Group” meansBarclays Bank PLC, Barclays PLC and any of their subsidiaries,affiliates,ultimate holding companyand any subsidiaries oraffiliatesof such holding company.CONFLICTS OF INTERESTBARCLAYS IS A FULL SERVICE INVESTMENT BANK. In the normal course ofofferinginvestment bankingproducts and services to clients, Barclays may act in several capacities (including issuer, market Peter Lawson, DPhil (Oxon) is a Managing Director andEquity Research Analyst covering the U.S. Small and MidCap Biotechnology sector, with over 15 years of sell-sideresearch experience. Before joining Barclays in December2019, Peter spent over four years at SunTrust RobinsonHumphrey as a Managing Director and Senior EquityResearch Analyst covering the Biotechnology sector. Peterserved as Executive Director and Senior Equity ResearchAnalyst covering the Biotechnology sector at MizuhoSecurities USA until September 2015, as well as ManagingDirector and Equity Analyst covering the Life Science Toolssector at Thomas Weisel Partners until July 2010. Petergraduated from the University of Oxford with a DPhil inBiochemistry and holds a BSc in Physiology fromUniversity College London.View Analyst Page maker and/or liquidity provider, underwriter, distributor, index sponsor, swap counterparty andcalculation agent) simultaneously with respect to a product, giving rise to potential conflicts ofinterest which may impact the performance of a product.BARCLAYS POSITIONSBarclays may at any time acquire, hold or dispose of long or short positions (including hedging andtrading positions) and trade or otherwiseeffecttransactions for their own account or the account oftheir customers in the products referred to herein which may impact the performance of a product.FOR INFORMATION ONLYTHIS DOCUMENT IS PROVIDED FOR INFORMATION PURPOSES ONLY AND IT IS SUBJECT TO CHANGE.This information has been prepared by the Research Department within the Investment Bank ofBarclays. The information, analytic tools, and/or models referenced herein (and any reports or resultsderived from their use) are intended for informational purposes only. Barclays has no obligation toupdate this information and may cease provision of this information at any time and without notice.NO OFFERBarclays is notofferingto sell or seekingoffersto buy any product or enter into any transaction. Anyofferor entry into any transaction requires Barclays’ subsequent formal agreement which will besubject to internal approvals and execution of binding transaction documents. The productsmentioned may not be eligible for sale in some states or countries, nor suitable for all types ofinvestors. Without limitation to the foregoing, any transaction may also be subject to review byBarclays Group against its published Tax Principles.NO LIABILITYNeither Barclays nor any of its directors,officers,employees, representatives or agents, accepts anyliability whatsoever for any direct, indirect or consequential losses (in contract,